JP Morgan Initiates Esperion Therapeutics With Overweight

Analysts at JP Morgan initiated coverage on Esperion Therapeutics Inc ESPR with a Overweight rating. The target price for Esperion Therapeutics is set to $130. Esperion Therapeutics shares have gained 454.22 percent over the past 52 weeks, while the S&P 500 index has surged 7.73 percent in the same period. Esperion Therapeutics' shares jumped 0.08 percent to $84.09 in after-hours trading.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: InitiationAnalyst RatingsJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!